Market PotentialSebetralstat, if approved, will be the first oral on-demand therapy for acute HAE, addressing the inconvenience of existing injectable therapies.
Market StrategyThe company's proactive strategy and readiness for the commercial launch of sebetralstat suggests strong potential for success post-approval.
Product DevelopmentKalVista Pharmaceuticals is making significant progress in developing sebetralstat, an oral plasma kallikrein inhibitor, for the treatment of hereditary angioedema.